59 related articles for article (PubMed ID: 21826878)
1. Blood donors: an ideal population to study the PSA value and the incidence of prostate cancer in healthy population.
Fandella A; Borghesi M; Bertaccini A
Arch Ital Urol Androl; 2011 Jun; 83(2):75-7. PubMed ID: 21826878
[TBL] [Abstract][Full Text] [Related]
2. [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre].
Khouaja K; Ben Sorba N; Bouslama A; Youssef A; Taher Mosbah A
Prog Urol; 2005 Apr; 15(2):255-9. PubMed ID: 15999603
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ml) and percent free PSA cutoff values of 15 and 20%.
Pepe P; Panella P; Savoca F; Cacciola A; D'Arrigo L; Dibenedetto G; Pennisi M; Aragona F
Urol Int; 2007; 78(4):308-12. PubMed ID: 17495487
[TBL] [Abstract][Full Text] [Related]
5. The patients less than 50 years: is there a need to lower the PSA cutoff point?
Hekal IA
Prostate Cancer Prostatic Dis; 2009; 12(2):148-51. PubMed ID: 18825164
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal evaluation of prostate-specific antigen levels in a case-control study.
De Biasi F; Londero D; Praturlon S; Di Donna A; Feruglio GA; Guerra UP
Eur Urol; 1996; 29(2):184-8. PubMed ID: 8647144
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
8. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
10. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
[TBL] [Abstract][Full Text] [Related]
11. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
Postma R; de Vries SH; Roobol MJ; Wildhagen MF; Schröder FH; van der Kwast TH
Cancer; 2005 Feb; 103(4):708-16. PubMed ID: 15648082
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
13. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
14. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
16. Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients.
Pepe P; Aragona F
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):316-9. PubMed ID: 20714341
[TBL] [Abstract][Full Text] [Related]
17. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
Rahardjo D; Kamil ST; Pakasi LS
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
[TBL] [Abstract][Full Text] [Related]
18. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
19. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
20. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]